Literature DB >> 2710561

Pain responses to perineuromal injection of normal saline, gallamine, and lidocaine in humans.

C Chabal1, L Jacobson, L C Russell, K J Burchiel.   

Abstract

Rat neurons have shown an increase of spontaneously active fibers to systemically administered potassium channel blocking agents such as tetraethylammonium chloride (TEA) and gallamine. Neuroma formation and spontaneous activity have been associated with autotomy in rats and pain in humans. To evaluate the chemosensitivity of human neurons to potassium channel blocking agents, 9 subjects with neuroma pain underwent perineuromal injection in a single-blinded fashion of normal saline, gallamine, and lidocaine. Sodium had no effect on control pain levels, while gallamine significantly increased and lidocaine significantly decreased pain from control levels. Three of 4 patients with accompanying phantom limb pain noted an increase in pain after the injection of gallamine. The data suggest that peripheral input plays a modulating but not solitary role in both neuroma and phantom limb pain. Agents which increase potassium channel permeability or decrease sodium influx would be predicted to decreased perceived pain.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2710561     DOI: 10.1016/0304-3959(89)90091-2

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  14 in total

1.  Downregulation of tetrodotoxin-resistant sodium currents and upregulation of a rapidly repriming tetrodotoxin-sensitive sodium current in small spinal sensory neurons after nerve injury.

Authors:  T R Cummins; S G Waxman
Journal:  J Neurosci       Date:  1997-05-15       Impact factor: 6.167

2.  Multiple interacting sites of ectopic spike electrogenesis in primary sensory neurons.

Authors:  Ron Amir; Jeffery D Kocsis; Marshall Devor
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

Review 3.  Sodium channel blockers for the treatment of neuropathic pain.

Authors:  Anindya Bhattacharya; Alan D Wickenden; Sandra R Chaplan
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

Review 4.  Optimal treatment of phantom limb pain in the elderly.

Authors:  R Baron; G Wasner; V Lindner
Journal:  Drugs Aging       Date:  1998-05       Impact factor: 3.923

5.  A long noncoding RNA contributes to neuropathic pain by silencing Kcna2 in primary afferent neurons.

Authors:  Xiuli Zhao; Zongxiang Tang; Hongkang Zhang; Fidelis E Atianjoh; Jian-Yuan Zhao; Lingli Liang; Wei Wang; Xiaowei Guan; Sheng-Chin Kao; Vinod Tiwari; Yong-Jing Gao; Paul N Hoffman; Hengmi Cui; Min Li; Xinzhong Dong; Yuan-Xiang Tao
Journal:  Nat Neurosci       Date:  2013-06-23       Impact factor: 24.884

6.  A randomized controlled study to evaluate the efficacy of noninvasive limb cover for chronic phantom limb pain among veteran amputees.

Authors:  An-Fu Hsiao; Robyn York; Ian Hsiao; Ed Hansen; Ron D Hays; John Ives; Ian D Coulter
Journal:  Arch Phys Med Rehabil       Date:  2012-04       Impact factor: 3.966

7.  Nerve growth factor maintains potassium conductance after nerve injury in adult cutaneous afferent dorsal root ganglion neurons.

Authors:  B Everill; J D Kocsis
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

8.  Nitric oxide implicates c-Fos expression in the cuneate nucleus following electrical stimulation of the transected median nerve.

Authors:  Hsin-Ying Wang; Yi-Ju Tsai; Seu-Hwa Chen; Chi-Te Lin; June-Horng Lue
Journal:  Neurochem Res       Date:  2011-09-03       Impact factor: 3.996

Review 9.  Noncoding RNAs: new players in chronic pain.

Authors:  Brianna Marie Lutz; Alex Bekker; Yuan-Xiang Tao
Journal:  Anesthesiology       Date:  2014-08       Impact factor: 7.892

10.  John J. Bonica Award Lecture: Peripheral neuronal hyperexcitability: the "low-hanging" target for safe therapeutic strategies in neuropathic pain.

Authors:  Srinivasa N Raja; Matthias Ringkamp; Yun Guan; James N Campbell
Journal:  Pain       Date:  2020-09       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.